Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Interferon alpha 2b, Recombinant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CytomX to Present Data for Conditionally Activated Interferon Alpha-2b
    CytomX to Present Data for Conditionally Activated Interferon Alpha-2b

    30 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/30/2769158/37704/en/CytomX-Therapeutics-to-Present-Preclinical-Data-for-Conditionally-Activated-Interferon-Alpha-2b-at-the-SITC-2023-Annual-Meeting.html

    GLOBENEWSWIRE
    30 Oct 2023
    Share Share
    BetterLife Initiates Preclinical Study of AP-003 in Delta Variant of SARS-CoV-2
    BetterLife Initiates Preclinical Study of AP-003 in Delta Variant of SARS-CoV-2

    25 Aug 2021

    // GLOBENEWSWIRE

    https://www.pharmacompass.com/pdf/news/betterlife-initiates-preclinical-study-of-ap-003-in-delta-variant-of-sars-cov-2-1631603417.pdf

    GLOBENEWSWIRE
    25 Aug 2021
    Share Share
    AOP Orphan Pharmaceuticals presents latest analysis on BESREMi at EHA 2021
    AOP Orphan Pharmaceuticals presents latest analysis on BESREMi at EHA 2021

    01 Jul 2021

    // PRESS RELEASE

    https://www.aoporphan.com/se_en/our-company/newsroom/aop-orphan-pharmaceuticals-presents-latest-analysis-on-besremi-r-ropeginterferon-alfa-2b-in-polycythaemia-vera-at-the-prestigious-european-hematology-association-eha-annual-meeting-2021

    PRESS RELEASE
    01 Jul 2021
    Share Share
    Schering's Peginterferon Alfa-2B Receives Approval in US
    Schering's Peginterferon Alfa-2B Receives Approval in US

    08 Jan 2019

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103949

    FDA
    08 Jan 2019
    Share Share
    Schering's Peginterferon Alfa-2B Receives Supplemental Approval in US
    Schering's Peginterferon Alfa-2B Receives Supplemental Approval in US

    21 Dec 2018

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103949

    FDA
    21 Dec 2018
    Share Share
    Schering's Peginterferon Alfa-2B Receives Supplemental Approval in US
    Schering's Peginterferon Alfa-2B Receives Supplemental Approval in US

    21 Dec 2018

    //

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103949

    21 Dec 2018
    Share Share